SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    KASL clinical practice guidelines: Management of Hepatitis C, Clinical and Molecular Hepatology, 2014, 20, 2, 89

    CrossRef

  2. 2
    H.M. Dabbous, M.S. Elmeteini, M.A. Sakr, I.F. Montasser, M. Bahaa, A. Abdelaal, M. Fathy, R. Refaie, M. Seyam, A. Abdelmonem, A. Mukhtar, N. Hegazy, M. Almoneiri, Optimizing Outcome of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplantation: Moving Forward by Looking Back, Transplantation Proceedings, 2014, 46, 3, 822

    CrossRef

  3. 3
    D. Cheng, E. Liu, Y. Li, R. Liu, L. Bai, Y. Chen, Y. Wang, Y. Chu, M. Wu, G. Cheng, S. Zhao, Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C, European Journal of Clinical Microbiology & Infectious Diseases, 2014, 33, 3, 433

    CrossRef

  4. 4
    Amal A. Mohamed, Magdi A. Amin, Mai M. Ragab, Soheir A. Ismail, Amin Abdel M. Baki, Protein kinase expression as a predictive factor for interferon response in chronic hepatitis C patients, Journal of Advanced Research, 2014, 5, 1, 117

    CrossRef

  5. 5
    Hany Shehab, Tamer Elbaz, Dalia Deraz, Amal Hafez, Inas Elattar, The Efficacy of aHansenula-Derived 20 kDa Pegylated Interferon Alpha-2a in the Treatment of Genotype 4 Chronic Hepatitis C, Journal of Interferon & Cytokine Research, 2014, 140414072225006

    CrossRef

  6. 6
    Clara T. M. M. de Kanter, Joost P. H. Drenth, Joop E. Arends, Henk W. Reesink, Marc van der Valk, Robert J. de Knegt, David M. Burger, Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations, Clinical Pharmacokinetics, 2014, 53, 5, 409

    CrossRef

  7. 7
    Lotte G. van Vlerken, Clara T.M.M. de Kanter, Greet J. Boland, Anton M. van Loon, Hanneke van Soest, Ger H. Koek, Joost P.H. Drenth, Peter D. Siersema, Karel J. van Erpecum, David M. Burger, Measuring Ribavirin Concentrations During the Earliest Stages of Antiviral Therapy for Hepatitis C, Therapeutic Drug Monitoring, 2013, 35, 4, 546

    CrossRef

  8. 8
    Daphne M. Hotho, Kim Kreefft, Zwier M.A. Groothuismink, Harry L.A. Janssen, Robert J. de Knegt, André Boonstra, Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: Early effects of active substance use, Antiviral Research, 2013, 97, 3, 347

    CrossRef

  9. 9
    Abdulrahman A. Aljumah, Mohammad Hassan Murad, Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis, Hepatology Research, 2013, 43, 12
  10. 10
    Peter Ferenci, Treatment of Chronic Hepatitis C, Genotype 4, Current Hepatitis Reports, 2013, 12, 4, 246

    CrossRef

  11. 11
    Christophe Moreno, Thomas Berg, Tawesak Tanwandee, Satawat Thongsawat, Hans Van Vlierberghe, Stefan Zeuzem, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a phase IIa, open-label study, Journal of Hepatology, 2012, 56, 6, 1247

    CrossRef

  12. 12
    Sudeep Tanwar, Paul M. Trembling, Geoffrey M. Dusheiko, Hepatitis C Therapy: Lessons of the Last Two Decades, Current Hepatitis Reports, 2012, 11, 3, 119

    CrossRef

  13. 13
    Vasilios Papastergiou, Dimitrios Dimitroulopoulos, Lamprini Skorda, Philippos Lisgos, Ioannis Ketikoglou, Nikolaos Kostas, Stylianos Karatapanis, Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?, Journal of Medical Virology, 2012, 84, 8
  14. 14
    Hamad I. Al-Ashgar, Mohammed Q. Khan, Ahmed Helmy, Sahar Al-Thawadi, Mohammed N. Al-Ahdal, Nisreen Khalaf, Ahmed Al-Qahtani, Faisal M Sanai, Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4, European Journal of Gastroenterology & Hepatology, 2012, 1

    CrossRef

  15. 15
    Samuel James Matthews, Jason W. Lancaster, Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor, Clinical Therapeutics, 2012, 34, 9, 1857

    CrossRef

  16. 16
    Rosario González-Casas, María Trapero-Marugán, Ricardo Moreno-Otero, Hepatitis crónica por virus de la hepatitis C genotipo 4, Medicina Clínica, 2011, 137, 1, 31

    CrossRef

  17. 17
    Mahmoud A. Khattab, Peter Ferenci, Stephanos J. Hadziyannis, Massimo Colombo, Michael P. Manns, Piero L. Almasio, Rafael Esteban, Ayman A. Abdo, Stephen A. Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S. Lee, Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel, Journal of Hepatology, 2011, 54, 6, 1250

    CrossRef

  18. 18
    S. Zhao, E. Liu, K. Wei, Y. Wang, Y. Li, B. Huang, Y. Chen, P. Yang, Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C, European Journal of Clinical Microbiology & Infectious Diseases, 2011, 30, 1, 51

    CrossRef

  19. 19
    Narci C Teoh, Geoffrey C Farrell, Henry L-Y Chan, Individualisation of antiviral therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2010, 25, 7
  20. 20
    A. Ciancio, M. Rizzetto, Thymalfasin in the treatment of hepatitis B and C, Annals of the New York Academy of Sciences, 2010, 1194, 1
  21. 21
    James Fung, Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic, Expert Review of Anti-infective Therapy, 2009, 7, 8, 945

    CrossRef

  22. You have full text access to this OnlineOpen article22
    Marc G. Ghany, Doris B. Strader, David L. Thomas, Leonard B. Seeff, Diagnosis, management, and treatment of hepatitis C: An update, Hepatology, 2009, 49, 4
  23. 23
    F. Negro, S. Clément, Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C, Journal of Viral Hepatitis, 2009, 16, 10
  24. 24
    Andrew Aronsohn, Nancy Reau, Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients, Journal of Clinical Gastroenterology, 2009, 43, 7, 661

    CrossRef

  25. 25
    Hesham El Makhzangy, Gamal Esmat, Mohamed Said, Maissa ElRaziky, Soheir Shouman, Rasha Refai, Claire Rekacewicz, Rita Raafat Gad, Nicolas Vignier, Mohamed Abdel-Hamid, Khaled Zalata, Pierre Bedossa, Stanislas Pol, Arnaud Fontanet, Mostafa K. Mohamed, Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4, Journal of Medical Virology, 2009, 81, 9
  26. 26
    Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Tahany Awad, Cochrane Database of Systematic Reviews, 2009,

    CrossRef

  27. 27
    Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Tahany Awad, Cochrane Database of Systematic Reviews, 2009,

    CrossRef

  28. 28
    Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Tahany Awad, Cochrane Database of Systematic Reviews, 2009,

    CrossRef

  29. 29
    Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Tahany Awad, Cochrane Database of Systematic Reviews, 2009,

    CrossRef

  30. 30
    Richard Njouom, Michèle Tagni Sartre, Isabelle Timba, Eric Nerrienet, Patrice Tchendjou, Christophe Pasquier, Dominique Rousset, Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C, Journal of Medical Virology, 2008, 80, 12
  31. 31
    Sanaa M. Kamal, Imad A. Nasser, Hepatitis C genotype 4: What we know and what we don't yet know, Hepatology, 2008, 47, 4
  32. 32
    R. Chou, S. Carson, B. K. S. Chan, Pegylated interferons for chronic hepatitis C virus infection: an indirect analysis of randomized trials, Journal of Viral Hepatitis, 2008, 15, 8
  33. 33
    Shahzad Iqbal, Mohamad Mansour, Maurice A. Cerulli, Shorter Treatment for Hepatitis C Genotype 4 May Be a Possibility, Southern Medical Journal, 2008, 101, 1, 106

    CrossRef

  34. 34
    Annika Kau, Johannes Vermehren, Christoph Sarrazin, Treatment predictors of a sustained virologic response in hepatitis B and C, Journal of Hepatology, 2008, 49, 4, 634

    CrossRef

  35. 35
    Sanaa M. Kamal, Improving Outcome in Patients With Hepatitis C Virus Genotype 4, The American Journal of Gastroenterology, 2007, 102, 11, 2582

    CrossRef

  36. 36
    Sanaa M. Kamal, Samer S. El Kamary, Michelle D. Shardell, Mohamed Hashem, Imad N. Ahmed, Mohamed Muhammadi, Khalifa Sayed, Ashraf Moustafa, Sarah Abdel Hakem, Amany Ibrahiem, Mohamed Moniem, Hoda Mansour, Mohamed Abdelaziz, Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response, Hepatology, 2007, 46, 6
  37. 37
    Eric Nguyen-Khac, Dominique Capron, Sandrine Castelain, Catherine François, Alain Braillon, Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?, European Journal of Internal Medicine, 2007, 18, 7, 510

    CrossRef

  38. 38
    S. Ramia, J. Eid-Fares, Distribution of hepatitis C virus genotypes in the Middle East, International Journal of Infectious Diseases, 2006, 10, 4, 272

    CrossRef

  39. 39
    Sanaa M. Kamal, Genotypic variations around the world: Is hepatitis C virus evolving?, Current Hepatitis Reports, 2006, 5, 4, 142

    CrossRef

  40. 40
    Jean Delwaide, Catherine Reenaers, Christiane Gerard, Dolores Vaira, Boris Bastens, Beno??t Servais, Abdelaziz Bekhti, Christian Bataille, Etienne Wain, Pascal De Leeuw, Guy Daenen, Thierry Mesureur, Jean-Marie Sente, Jacques Bela??che, HCV genotype 4 in Belgium: three distinct patterns among patients from European and African origin, European Journal of Gastroenterology & Hepatology, 2006, 18, 7, 707

    CrossRef

  41. 41
    Markus Cornberg, Katja Deterding, Michael P Manns, Present and future therapy for hepatitis C virus, Expert Review of Anti-infective Therapy, 2006, 4, 5, 781

    CrossRef

  42. 42
    Jeanne Serpaggi, Marie-Laure Chaix, Dominique Batisse, Caroline Dupont, Anaïs Vallet-Pichard, Hélène Fontaine, Jean-Paul Viard, Christophe Piketty, Elisabeth Rouveix, Christine Rouzioux, Laurence Weiss, Stanislas Pol, Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy, AIDS, 2006, 20, 2, 233

    CrossRef

  43. 43
    M. Diago Madrid, Tratamiento de pacientes genotipo 4, Gastroenterología y Hepatología, 2006, 29, 146

    CrossRef

  44. 44
    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili, Ran Tur-Kaspa, Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response, The Cochrane Library,
  45. 45
    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili, Ran Tur-Kaspa, Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients, The Cochrane Library,
  46. 46
    Sanaa M. Kamal, Hepatitis C Genotype 4 Therapy: Progress and Challenges,
  47. 47
    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud, Lise Lotte Gluud, Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C, The Cochrane Library,
  48. 48
    Tahany Awad, Kristian Thorlund, Goran Hauser, Mahasen Mabrouk, Davor Stimac, Christian Gluud, Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C, The Cochrane Library,
  49. 49
    Marija Simin, Jesper Brok, Davor Stimac, Christian Gluud, Lise Lotte Gluud, Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C, The Cochrane Library,
  50. 50
    Tahany Awad, Jesper Brok, Kristian Thorlund, Goran Hauser, Davor Stimac, Mahasen Mabrouk, Christian Gluud, Lise Lotte Gluud, Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C, The Cochrane Library,